Amneal Pharmaceuticals, LLC, the 7th largest generic drug manufacturer in the U.S. market, has received U.S. FDA approval for one of the first generic versions of Suboxone® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles.
Source: NewsMedical.net – February 25, 2013
Note: On February 26, 2013 the FDA also approved Actavis’ generic Suboxone for treatment of opioid dependence.
Source: NewsMedical.net – February 26, 2013